EGFR and non-small cell lung carcinoma: Although osimertinib is undoubtedly the key drug for postoperative adjuvant therapy in EGFR‐mutated NSCLC, platinum‐based chemotherapy prior to osimertinib remains the standard based on the ADAURA study design.